Metronidazole
 Metronidazole injection

drug-information.ru

|Metronidazole Metronidazole injection

Drugs search, click the first letter of a drug name:


| A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z | 1 | 2 | 3 | 4 | 5 | 6 | 8 | 9  Home

Metronidazole


Generic Name: Metronidazole
Dosage Form: Tablets usp

Warning

To reduce the development of drug-resistant bacteria and maintain the effectiveness of Metronidazole tablets and other antibacterial drugs, Metronidazole tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria.

Metronidazole has been shown to be carcinogenic in mice and rats. (See PRECAUTIONS.) Unnecessary use of the drug should be avoided. Its use should be reserved for the conditions described in the INDICATIONS AND USAGE section below.

Metronidazole Description

Metronidazole is an oral synthetic antiprotozoal and antibacterial agent, 1-(β-hydroxyethyl)-2-methyl-5-nitroimidazole. The structural formula is represented below:

C6H9N3O3      M.W. 171.15

Each tablet, for oral administration, contains 250 mg or 500 mg of Metronidazole. In addition, each tablet contains the following inactive ingredients: colloidal silicon dioxide, crospovidone, hydrogenated vegetable oil and microcrystalline cellulose.

Metronidazole - Clinical Pharmacology

Disposition of Metronidazole in the body is similar for both oral and intravenous dosage forms, with an average elimination half-life in healthy humans of eight hours.

The major route of elimination of Metronidazole and its metabolites is via the urine (60 to 80% of the dose), with fecal excretion accounting for 6 to 15% of the dose. The metabolites that appear in the urine result primarily from side-chain oxidation [1-(β-hydroxyethyl)-2-hydroxymethyl-5- nitroimidazole and 2-methyl-5-nitroimidazole-1-yl-acetic acid] and glucuronide conjugation, with unchanged Metronidazole accounting for approximately 20% of the total. Renal clearance of Metronidazole is approximately 10 mL/min/1.73 m2.

Metronidazole is the major component appearing in the plasma, with lesser quantities of the 2-hydroxymethyl metabolite also being present. Less than 20% of the circulating Metronidazole is bound to plasma proteins. Both the parent compound and the metabolite possess in vitro bactericidal activity against most strains of anaerobic bacteria and in vitro trichomonacidal activity.

Metronidazole appears in cerebrospinal fluid, saliva, and human milk in concentrations similar to those found in plasma. Bactericidal concentrations of Metronidazole have also been detected in pus from hepatic abscesses.

Following oral administration, Metronidazole is well absorbed, with peak plasma concentrations occurring between one and two hours after administration. Plasma concentrations of Metronidazole are proportional to the administered dose. Oral administration of 250 mg, 500 mg, or 2,000 mg produced peak plasma concentrations of 6 mcg/mL, 12 mcg/mL, and 40 mcg/mL, respectively. Studies reveal no significant bioavailability differences between males and females; however, because of weight differences, the resulting plasma levels in males are generally lower.

Decreased renal function does not alter the single-dose pharmacokinetics of Metronidazole. However, plasma clearance of Metronidazole is decreased in patients with decreased liver function.

Microbiology

Trichomonas vaginalis, Entamoeba histolytica

Metronidazole possesses direct trichomonacidal and amebacidal activity against T. vaginalis and E. histolytica. The in vitro minimal inhibitory concentration (MIC) for most strains of these organisms is 1 mcg/mL or less.

Anaerobic Bacteria

Metronidazole is active in vitro against most obligate anaerobes but does not appear to possess any clinically relevant activity against facultative anaerobes or obligate aerobes. Against susceptible organisms, Metronidazole is generally bactericidal at concentrations equal to or slightly higher than the minimal inhibitory concentrations. Metronidazole has been shown to have in vitro and clinical activity against the following organisms:

Anaerobic gram-negative bacilli, including:

Bacteroides species including the Bacteroides fragilis group (B. fragilis, B.ovatus , B.distasonis, B. thetaiotaomicron, B. vulgatus)

Fusobacterium species

Anaerobic gram-positive bacilli, including:

Clostridium species and susceptible strains of Eubacterium

Anaerobic gram-positive cocci, including:

Peptococcus niger

Peptostreptococcus species

Susceptibility Tests

Bacteriologic studies should be performed to determine the causative organisms and their susceptibility to Metronidazole; however, the rapid, routine susceptibility testing of individual isolates of anaerobic bacteria is not always practical, and therapy may be started while awaiting these results.

Quantitative methods give the most precise estimates of susceptibility to antibacterial drugs. A standardized agar dilution method and a broth microdilution method are recommended1.

Control strains are recommended for standardized susceptibility testing. Each time the test is performed, one or more of the following strains should be included: Clostridium perfringens ATCC 13124, Bacteroides fragilis ATCC 25285, and Bacteroides thetaiotaomicron ATCC 29741. The mode Metronidazole MICs for those three strains are reported to be 0.25, 0.25, and 0.5 mcg/mL, respectively.

A clinical laboratory is considered under acceptable control if the results of the control strains are within one doubling dilution of the mode MICs reported for Metronidazole.

A bacterial isolate may be considered susceptible if the MIC value for Metronidazole is not more than 16 mcg/mL. An organism is considered resistant if the MIC is greater than 16 mcg/mL. A report of “resistant” from the laboratory indicates that the infecting organism is not likely to respond to therapy.

Indications and Usage for Metronidazole

Symptomatic Trichomoniasis

Metronidazole is indicated for the treatment of symptomatic trichomoniasis in females and males when the presence of the trichomonad has been confirmed by appropriate laboratory procedures (wet smears and/or cultures).

Asymptomatic Trichomoniasis

Metronidazole is indicated in the treatment of asymptomatic females when the organism is associated with endocervicitis, cervicitis, or cervical erosion. Since there is evidence that presence of the trichomonad can interfere with accurate assessment of abnormal cytological smears, additional smears should be performed after eradication of the parasite.

Treatment of Asymptomatic Consorts

T. vaginalis infection is a venereal disease. Therefore, asymptomatic sexual partners of treated patients should be treated simultaneously if the organism has been found to be present, in order to prevent reinfection of the partner. The decision as to whether to treat an asymptomatic male partner who has a negative culture or one for whom no culture has been attempted is an individual one. In making this decision, it should be noted that there is evidence that a woman may become reinfected if her consort is not treated. Also, since there can be considerable difficulty in isolating the organism from the asymptomatic male carrier, negative smears and cultures cannot be relied upon in this regard. In any event, the consort should be treated with Metronidazole in cases of reinfection.

Amebiasis

Metronidazole is indicated in the treatment of acute intestinal amebiasis (amebic dysentery) and amebic liver abscess.

In amebic liver abscess, Metronidazole therapy does not obviate the need for aspiration or drainage of pus.

Anaerobic Bacterial Infections

Metronidazole is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. Indicated surgical procedures should be performed in conjunction with Metronidazole therapy. In a mixed aerobic and anaerobic infection, antimicrobials appropriate for the treatment of the aerobic infection should be used in addition to Metronidazole.

In the treatment of most serious anaerobic infections, the intravenous form of Metronidazole is usually administered initially. This may be followed by oral therapy with Metronidazole at the discretion of the physician.

INTRA-ABDOMINAL INFECTIONS, including peritonitis, intra-abdominal abscess, and liver abscess, caused by Bacteroides species including the B. fragilis group (B. fragilis, B. distasonis,B. ovatus, B. thetaiotaomicron, B. vulgatus), Clostridium species, Eubacterium species, Peptococcus niger, and Peptostreptococcus species.

SKIN AND SKIN STRUCTURE INFECTIONS caused by Bacteroides species including the B . fragilis group, Clostridium species, Peptococcus niger, Peptostreptococcus species, and Fusobacterium species.

GYNECOLOGIC INFECTIONS, including endometritis, endomyometritis, tubo-ovarian abscess, and post-surgical vaginal cuff infection, caused by Bacteroides species including the B. fragilis group, Clostridium species, Peptococcus niger, and Peptostreptococcus species.

BACTERIAL SEPTICEMIA caused by Bacteroides species including the B. fragilis group, and Clostridium species.

BONE AND JOINT INFECTIONS, as adjunctive therapy, caused by Bacteroides species including the B. fragilis group.

CENTRAL N E RVOUS SYSTEM (CNS) INFECTIONS, including meningitis and brain abscess, caused by Bacteroides species including the B. fragilis group.

LOWER RESPIRATO RY TRACT INFECTIONS, including pneumonia, empyema, and lung abscess, caused by Bacteroides species including the B. fragilis group.

ENDOCARDITIS caused by Bacteroides species including the B. fragilis group.

To reduce the development of drug-resistant bacteria and maintain the effectiveness of Metronidazole tablets and other antibacterial drugs, Metronidazole tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.

Contraindications

Metronidazole is contraindicated in patients with a prior history of hypersensitivity to Metronidazole or other nitroimidazole derivatives.

In patients with trichomoniasis, Metronidazole is contraindicated during the first trimester of pregnancy. (See PRECAUTIONS.)

Warnings

Convulsive Seizures and Peripheral Neuropathy

Convulsive seizures and peripheral neuropathy, the latter characterized mainly by numbness or paresthesia of an extremity, have been reported in patients treated with Metronidazole. The appearance of abnormal neurologic signs demands the prompt discontinuation of Metronidazole therapy. Metronidazole should be administered with caution to patients with central nervous system diseases.

Precautions

General

Patients with severe hepatic disease metabolize Metronidazole slowly, with resultant accumulation of Metronidazole and its metabolites in the plasma. Accordingly, for such patients, doses below those usually recommended should be administered cautiously.

Known or previously unrecognized candidiasis may present more prominent symptoms during therapy with Metronidazole and requires treatment with a candidacidal agent.

Prescribing Metronidazole tablets in the absence of a proven or strongly suspected bacterial infection or a prophylactic indication is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria.

Information for Patients

Alcoholic beverages should be avoided while taking Metronidazole and for at least one day afterward. (See Drug Interactions.)

Patients should be counseled that antibacterial drugs including Metronidazole tablets should only be used to treat bacterial infections. They do not treat viral infections (e.g., the common cold). When Metronidazole tablets are prescribed to treat a bacterial infection, patients should be told that although it is common to feel better early in the course of therapy, the medication should be taken exactly as directed. Skipping doses or not completing the full course of therapy may (1) decrease the effectiveness of the immediate treatment and (2) increase the likelihood that bacteria will develop resistance and will not be treatable by Metronidazole tablets or other antibacterial drugs in the future.

Laboratory Tests

Metronidazole is a nitroimidazole and should be used with caution in patients with evidence of or history of blood dyscrasia. A mild leukopenia has been observed during its administration; however, no persistent hematologic abnormalities attributable to Metronidazole have been observed in clinical studies. Total and differential leukocyte counts are recommended before and after therapy for trichomoniasis and amebiasis, especially if a second course of therapy is necessary, and before and after therapy for anaerobic infections.

Drug Interactions

Metronidazole has been reported to potentiate the anticoagulant effect of warfarin and other oral coumarin anticoagulants, resulting in a prolongation of prothrombin time. This possible drug interaction should be considered when Metronidazole is prescribed for patients on this type of anticoagulant therapy.

The simultaneous administration of drugs that induce microsomal liver enzymes, such as phenytoin or phenobarbital, may accelerate the elimination of Metronidazole, resulting in reduced plasma levels; impaired clearance of phenytoin has also been reported.

The simultaneous administration of drugs that decrease microsomal liver enzyme activity, such as cimetidine, may prolong the half-life and decrease plasma clearance of Metronidazole. In patients stabilized on relatively high doses of lithium, short-term Metronidazole therapy has been associated with elevation of serum lithium and, in a few cases, signs of lithium toxicity. Serum lithium and serum creatinine levels should be obtained several days after beginning Metronidazole to detect any increase that may precede clinical symptoms of lithium intoxication.

Alcoholic beverages should not be consumed during Metronidazole therapy and for at least one day afterward because abdominal cramps, nausea, vomiting, headaches, and flushing may occur.

Psychotic reactions have been reported in alcoholic patients who are using Metronidazole and disulfiram concurrently. Metronidazole should not be given to patients who have taken disulfiram within the last two weeks.

Drug/Laboratory Test Interactions

Metronidazole may interfere with certain types of determinations of serum chemistry values, such as aspartate aminotransferase (AST, SGOT), alanine aminotransferase (ALT, SGPT), lactate dehydrogenase (LDH), triglycerides, and hexokinase glucose. Values of zero may be observed. All of the assays in which interference has been reported involve enzymatic coupling of the assay to oxidation-reduction of nicotinamide adenine dinucleotide (NAD+ ↔ NADH). Interference is due to the similarity in absorbance peaks of NADH (340 nm) and Metronidazole (322 nm) at pH 7.

Carcinogenesis, Mutagenesis, Impairment of Fertility

Metronidazole has shown evidence of carcinogenic activity in a number of studies involving chronic, oral administration in mice and rats.

Prominent among the effects in the mouse was the promotion of pulmonary tumorigenesis. This has been observed in all six reported studies in that species, including one study in which the animals were dosed on an intermittent schedule (administration during every fourth week only). At very high dose levels (approx. 500 mg/kg/day which is approximately 33 times the most frequently recommended human dose for a 50 kg adult based on mg/kg body weight) there was a statistically significant increase in the incidence of malignant liver tumors in males. Also, the published results of one of the mouse studies indicate an increase in the incidence of malignant lymphomas as well as pulmonary neoplasms associated with lifetime feeding of the drug. All these effects are statistically significant.

Several long-term, oral-dosing studies in the rat have been completed. There were statistically significant increases in the incidence of various neoplasms, particularly in mammary and hepatic tumors, among female rats administered Metronidazole over those noted in the concurrent female control groups.

Two lifetime tumorigenicity studies in hamsters have been performed and reported to be negative.

Although Metronidazole has shown mutagenic activity in a number of in vitro assay systems, studies in mammals (in vivo) have failed to demonstrate a potential for genetic damage.

Fertility studies have been performed in mice at doses up to six times the maximum recommended human dose based on mg/m2 and have revealed no evidence of impaired fertility.

Pregnancy

Teratogenic Effects-Pregnancy Category B

Metronidazole crosses the placental barrier and enters the fetal circulation rapidly. Reproduction studies have been performed in rats at doses up to five times the human dose and have revealed no evidence of impaired fertility or harm to the fetus due to Metronidazole. No fetotoxicity was observed when Metronidazole was administered orally to pregnant mice at 20 mg/kg/day, approximately one and a half times the most frequently recommended human dose (750 mg/day) based on mg/kg body weight; however, in a single small study where the drug was administered intraperitoneally, some intrauterine deaths were observed. The relationship of these findings to the drug is unknown. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, and because Metronidazole is a carcinogen in rodents, this drug should be used during pregnancy only if clearly needed.

Use of Metronidazole for trichomoniasis during pregnancy should be restricted to those in whom alternative treatment has been inadequate. Use of Metronidazole for trichomoniasis in pregnancy should be carefully evaluated because Metronidazole crosses the placental barrier and its effects on the human fetal organogenesis are not known (see above).

Nursing Mothers

Because of the potential for tumorigenicity, shown for Metronidazole in mouse and rat studies, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother. Metronidazole is secreted in human milk in concentrations similar to those found in plasma.

Geriatric Use

Decreased renal function does not alter the single-dose pharmacokinetics of Metronidazole. However, plasma clearance of Metronidazole is decreased in patients with decreased liver function. Therefore, in elderly patients, monitoring of serum levels may be necessary to adjust the Metronidazole dosage accordingly.

Pediatric Use

Safety and effectiveness in pediatric patients have not been established, except for the treatment of amebiasis.

Adverse Reactions

Two serious adverse reactions reported in patients treated with Metronidazole have been convulsive seizures and peripheral neuropathy, the latter characterized mainly by numbness or paresthesia of an extremity. Since persistent peripheral neuropathy has been reported in some patients receiving prolonged administration of Metronidazole, patients should be specifically warned about these reactions and should be told to stop the drug and report immediately to their physicians if any neurologic symptoms occur.

The most common adverse reactions reported have been referable to the gastrointestinal tract, particularly nausea reported by about 12% of patients, sometimes accompanied by headache, anorexia, and occasionally vomiting; diarrhea; epigastric distress; and abdominal cramping. Constipation has also been reported.

The following reactions have also been reported during treatment with Metronidazole:

Mouth

A sharp, unpleasant metallic taste is not unusual. Furry tongue, glossitis, and stomatitis have occurred; these may be associated with a sudden overgrowth of Candida which may occur during therapy.

Hematopoietic

Reversible neutropenia (leukopenia); rarely, reversible thrombocytopenia.

Cardiovascular

Flattening of the T-wave may be seen in electrocardiographic tracings.

Central Nervous System

Convulsive seizures, peripheral neuropathy, dizziness, vertigo, incoordination, ataxia, confusion, irritability, depression, weakness, and insomnia.

Hypersensitivity

Urticaria, erythematous rash, flushing, nasal congestion, dryness of the mouth (or vagina or vulva), and fever.

Renal

Dysuria, cystitis, polyuria, incontinence, and a sense of pelvic pressure. Instances of darkened urine have been reported by approximately one patient in 100,000. Although the pigment which is probably responsible for this phenomenon has not been positively identified, it is almost certainly a metabolite of Metronidazole and seems to have no clinical significance.

Other

Proliferation of Candida in the vagina, dyspareunia, decrease of libido, proctitis, and fleeting joint pains sometimes resembling “serum sickness.” If patients receiving Metronidazole drink alcoholic beverages, they may experience abdominal distress, nausea, vomiting, flushing, or headache. A modification of the taste of alcoholic beverages has also been reported. Rare cases of pancreatitis, which generally abated on withdrawal of the drug, have been reported.

Crohn’s disease patients are known to have an increased incidence of gastrointestinal and certain extraintestinal cancers. There have been some reports in the medical literature of breast and colon cancer in Crohn’s disease patients who have been treated with Metronidazole at high doses for extended periods of time. A cause and effect relationship has not been established. Crohn’s disease is not an approved indication for Metronidazole.

Overdosage

Single oral doses of Metronidazole, up to 15 g, have been reported in suicide attempts and accidental overdoses. Symptoms reported include nausea, vomiting, and ataxia.

Oral Metronidazole has been studied as a radiation sensitizer in the treatment of malignant tumors. Neurotoxic effects, including seizures and peripheral neuropathy, have been reported after 5 to 7 days of doses of 6 to 10.4 g every other day.

Treatment

There is no specific antidote for Metronidazole overdose; therefore, management of the patient should consist of symptomatic and supportive therapy.

Metronidazole Dosage and Administration

In elderly patients, the pharmacokinetics of Metronidazole may be altered, and, therefore, monitoring of serum levels may be necessary to adjust the Metronidazole dosage accordingly.

Trichomoniasis

In the Female

One-day treatment— two grams of Metronidazole, given either as a single dose or in two divided doses of one gram each given in the same day.

Seven-day course of treatment— 250 mg three times daily for seven consecutive days. There is some indication from controlled comparative studies that cure rates as determined by vaginal smears, signs and symptoms, may be higher after a seven-day course of treatment than after a one-day treatment regimen.

The dosage regimen should be individualized. Single-dose treatment can assure compliance, especially if administered under supervision, in those patients who cannot be relied on to continue the seven-day regimen. A seven-day course of treatment may minimize reinfection by protecting the patient long enough for the sexual contacts to obtain appropriate treatment. Further, some patients may tolerate one treatment regimen better than the other.

Pregnant patients should not be treated during the first trimester. (See CONTRAINDICATIONS.) In pregnant patients in whom alternative treatment has been inadequate, the one-day course of therapy should not be used, as it results in higher serum levels which can reach the fetal circulation (see PRECAUTIONS, Pregnancy).

When repeat courses of the drug are required, it is recommended that an interval of four to six weeks elapse between courses and that the presence of the trichomonad be reconfirmed by appropriate laboratory measures. Total and differential leukocyte counts should be made before and after retreatment.

In the Male

Treatment should beindividualized as for the female.

Amebiasis

Adults

For acute intestinal amebiasis (acute amebic dysentery): 750 mg orally three times daily for 5 to 10 days.

For amebic liver abscess: 500 mg or 750 mg orally three times daily for 5 to 10 days.

Pediatric patients

35 to 50 mg/kg/24 hours, divided into three doses, orally for 10 days.

Anaerobic Bacterial Infections

In the treatment of most serious anaerobic infections, the intravenous form of Metronidazole is usually administered initially.

The usual adult oral dosage is 7.5 mg/kg every six hours (approx. 500 mg for a 70-kg adult). A maximum of 4 g should not be exceeded during a 24-hour period.

The usual duration of therapy is 7 to 10 days; however, infections of the bone and joint, lower respiratory tract, and endocardium may require longer treatment.

Patients with severe hepatic disease metabolize Metronidazole slowly, with resultant accumulation of Metronidazole and its metabolites in the plasma. Accordingly, for such patients, doses below those usually recommended should be administered cautiously. Close monitoring of plasma Metronidazole levels2 and toxicity is recommended.

The dose of Metronidazole should not be specifically reduced in anuric patients since accumulated metabolites may be rapidly removed by dialysis.

How is Metronidazole Supplied

Metronidazole Tablets USP 250 mg are 11/32״, unscored, round, white to off-white tablets imprinted DAN and 5540 supplied in bottles of 50, 100, 250, 500 and 1000.

Metronidazole Tablets USP 500 mg are 17/32״, scored, round, white to off-white tablets imprinted DAN and 5552 supplied in bottles of 50, 100, 250, 500 and 1000. Dispense in a well-closed, light-resistant container with child-resistant closure.

Store below 86°F (30°C).

Protect from light.

REFERENCES

  1. Proposed standard: PSM-11-Proposed Reference Dilution Procedure for Antimicrobic Susceptibility Testing of Anaerobic Bacteria, National Committee for Clinical Laboratory Standards; and Sutter, et al.: Collaborative Evaluation of a Proposed Reference Dilution Method of Susceptibility Testing of Anaerobic Bacteria, Antimicrob. Agents Chemother. 16:495-502 (Oct.) 1979; and Tally, et al.: In Vitro Activity of Thienamycin, Antimicrob. Agents Chemother. 14:436-438 (Sept.) 1978.

  2. Ralph, E.D., and Kirby, W.M.M.: Bioassay of Metronidazole With Either Anaerobic or Aerobic Incubation, J. Infect. Dis.132:587-591 (Nov.) 1975; or Gulaid, et al.: Determination of Metronidazole and Its Major Metabolites in Biological Fluids by High Pressure Liquid Chromatography, Br. J. Clin. Pharmacol. 6:430-432, 1978.


Metronidazole (Metronidazole)
PRODUCT INFO
Product Code 0591-5540 Dosage Form TABLET
Route Of Administration ORAL DEA Schedule
INGREDIENTS
Name (Active Moiety) Type Strength
Metronidazole (Metronidazole) Active 250 MILLIGRAM  In 1 TABLET
Colloidial silicon dioxide Inactive  
Crospovidone Inactive  
Hydrogenated vegtable oil Inactive  
Microcrystalline cellulose Inactive  
IMPRINT INFORMATION
Characteristic Appearance Characteristic Appearance
Color WHITE (White to off-white) Score 1
Shape ROUND Symbol false
Imprint Code DAN;5540 Coating false
Size 9mm
PACKAGING
# NDC Package Description Multilevel Packaging
1 0591-5540-50 50 TABLET In 1 BOTTLE None
2 0591-5540-01 100 TABLET In 1 BOTTLE None
3 0591-5540-25 250 TABLET In 1 BOTTLE None
4 0591-5540-05 500 TABLET In 1 BOTTLE None
5 0591-5540-10 1000 TABLET In 1 BOTTLE None

Metronidazole (Metronidazole)
PRODUCT INFO
Product Code 0591-5552 Dosage Form TABLET
Route Of Administration ORAL DEA Schedule
INGREDIENTS
Name (Active Moiety) Type Strength
Metronidazole (Metronidazole) Active 500 MILLIGRAM  In 1 TABLET
Colloidial silicon dioxide Inactive  
Crospovidone Inactive  
Hydrogenated vegtable oil Inactive  
Microcrystalline cellulose Inactive  
IMPRINT INFORMATION
Characteristic Appearance Characteristic Appearance
Color WHITE (White to off-white) Score 2
Shape ROUND Symbol false
Imprint Code DAN;5552 Coating false
Size 14mm
PACKAGING
# NDC Package Description Multilevel Packaging
1 0591-5552-50 50 TABLET In 1 BOTTLE None
2 0591-5552-01 100 TABLET In 1 BOTTLE None
3 0591-5552-25 250 TABLET In 1 BOTTLE None
4 0591-5552-05 500 TABLET In 1 BOTTLE None
5 0591-5552-10 1000 TABLET In 1 BOTTLE None

Revised: 11/2006





Where can I get more information about Metronidazole Metronidazole injection ? We recommend to use www.Drugs.com

Typical mistypes for Metronidazole Metronidazole injection
netronidazole metronidazole injection, ketronidazole metronidazole injection, jetronidazole metronidazole injection, mwtronidazole metronidazole injection, mstronidazole metronidazole injection, mdtronidazole metronidazole injection, mrtronidazole metronidazole injection, m4tronidazole metronidazole injection, m3tronidazole metronidazole injection, merronidazole metronidazole injection, mefronidazole metronidazole injection, megronidazole metronidazole injection, meyronidazole metronidazole injection, me6ronidazole metronidazole injection, me5ronidazole metronidazole injection, meteonidazole metronidazole injection, metdonidazole metronidazole injection, metfonidazole metronidazole injection, mettonidazole metronidazole injection, met5onidazole metronidazole injection, met4onidazole metronidazole injection, metrinidazole metronidazole injection, metrknidazole metronidazole injection, metrlnidazole metronidazole injection, metrpnidazole metronidazole injection, metr0nidazole metronidazole injection, metr9nidazole metronidazole injection, metrobidazole metronidazole injection, metromidazole metronidazole injection, metrojidazole metronidazole injection, metrohidazole metronidazole injection, metronudazole metronidazole injection, metronjdazole metronidazole injection, metronkdazole metronidazole injection, metronodazole metronidazole injection, metron9dazole metronidazole injection, metron8dazole metronidazole injection, metronisazole metronidazole injection, metronixazole metronidazole injection, metronicazole metronidazole injection, metronifazole metronidazole injection, metronirazole metronidazole injection, metronieazole metronidazole injection, metronidzzole metronidazole injection, metronidszole metronidazole injection, metronidwzole metronidazole injection, metronidqzole metronidazole injection, metronidaxole metronidazole injection, metronidasole metronidazole injection, metronidaaole metronidazole injection, metronidazile metronidazole injection, metronidazkle metronidazole injection, metronidazlle metronidazole injection, metronidazple metronidazole injection, metronidaz0le metronidazole injection, metronidaz9le metronidazole injection, metronidazoke metronidazole injection, metronidazope metronidazole injection, metronidazooe metronidazole injection, metronidazolw metronidazole injection, metronidazols metronidazole injection, metronidazold metronidazole injection, metronidazolr metronidazole injection, metronidazol4 metronidazole injection, metronidazol3 metronidazole injection, metronidazole netronidazole injection, metronidazole ketronidazole injection, metronidazole jetronidazole injection, metronidazole mwtronidazole injection, metronidazole mstronidazole injection, metronidazole mdtronidazole injection, metronidazole mrtronidazole injection, metronidazole m4tronidazole injection, metronidazole m3tronidazole injection, metronidazole merronidazole injection, metronidazole mefronidazole injection, metronidazole megronidazole injection, metronidazole meyronidazole injection, metronidazole me6ronidazole injection, metronidazole me5ronidazole injection, metronidazole meteonidazole injection, metronidazole metdonidazole injection, metronidazole metfonidazole injection, metronidazole mettonidazole injection, metronidazole met5onidazole injection, metronidazole met4onidazole injection, metronidazole metrinidazole injection, metronidazole metrknidazole injection, metronidazole metrlnidazole injection, metronidazole metrpnidazole injection, metronidazole metr0nidazole injection, metronidazole metr9nidazole injection, metronidazole metrobidazole injection, metronidazole metromidazole injection, metronidazole metrojidazole injection, metronidazole metrohidazole injection, metronidazole metronudazole injection, metronidazole metronjdazole injection, metronidazole metronkdazole injection, metronidazole metronodazole injection, metronidazole metron9dazole injection, metronidazole metron8dazole injection, metronidazole metronisazole injection, metronidazole metronixazole injection, metronidazole metronicazole injection, metronidazole metronifazole injection, metronidazole metronirazole injection, metronidazole metronieazole injection, metronidazole metronidzzole injection, metronidazole metronidszole injection, metronidazole metronidwzole injection, metronidazole metronidqzole injection, metronidazole metronidaxole injection, metronidazole metronidasole injection, metronidazole metronidaaole injection, metronidazole metronidazile injection, metronidazole metronidazkle injection, metronidazole metronidazlle injection, metronidazole metronidazple injection, metronidazole metronidaz0le injection, metronidazole metronidaz9le injection, metronidazole metronidazoke injection, metronidazole metronidazope injection, metronidazole metronidazooe injection, metronidazole metronidazolw injection, metronidazole metronidazols injection, metronidazole metronidazold injection, metronidazole metronidazolr injection, metronidazole metronidazol4 injection, metronidazole metronidazol3 injection, metronidazole metronidazole unjection, metronidazole metronidazole jnjection, metronidazole metronidazole knjection, metronidazole metronidazole onjection, metronidazole metronidazole 9njection, metronidazole metronidazole 8njection, metronidazole metronidazole ibjection, metronidazole metronidazole imjection, metronidazole metronidazole ijjection, metronidazole metronidazole ihjection, metronidazole metronidazole inhection, metronidazole metronidazole innection, metronidazole metronidazole inmection, metronidazole metronidazole inkection, metronidazole metronidazole iniection, metronidazole metronidazole inuection, metronidazole metronidazole injwction, metronidazole metronidazole injsction, metronidazole metronidazole injdction, metronidazole metronidazole injrction, metronidazole metronidazole inj4ction, metronidazole metronidazole inj3ction, metronidazole metronidazole injextion, metronidazole metronidazole injevtion, metronidazole metronidazole injeftion, metronidazole metronidazole injedtion, metronidazole metronidazole injecrion, metronidazole metronidazole injecfion, metronidazole metronidazole injecgion, metronidazole metronidazole injecyion, metronidazole metronidazole injec6ion, metronidazole metronidazole injec5ion, metronidazole metronidazole injectuon, metronidazole metronidazole injectjon, metronidazole metronidazole injectkon, metronidazole metronidazole injectoon, metronidazole metronidazole inject9on, metronidazole metronidazole inject8on, metronidazole metronidazole injectiin, metronidazole metronidazole injectikn, metronidazole metronidazole injectiln, metronidazole metronidazole injectipn, metronidazole metronidazole injecti0n, metronidazole metronidazole injecti9n, metronidazole metronidazole injectiob, metronidazole metronidazole injectiom, metronidazole metronidazole injectioj, metronidazole metronidazole injectioh, etronidazole metronidazole injection, mtronidazole metronidazole injection, meronidazole metronidazole injection, metonidazole metronidazole injection, metrnidazole metronidazole injection, metroidazole metronidazole injection, metrondazole metronidazole injection, metroniazole metronidazole injection, metronidzole metronidazole injection, metronidaole metronidazole injection, metronidazle metronidazole injection, metronidazoe metronidazole injection, metronidazol metronidazole injection, metronidazole metronidazole injection, metronidazole metronidazole injection, metronidazole etronidazole injection, metronidazole mtronidazole injection, metronidazole meronidazole injection, metronidazole metonidazole injection, metronidazole metrnidazole injection, metronidazole metroidazole injection, metronidazole metrondazole injection, metronidazole metroniazole injection, metronidazole metronidzole injection, metronidazole metronidaole injection, metronidazole metronidazle injection, metronidazole metronidazoe injection, metronidazole metronidazol injection, metronidazole metronidazoleinjection, metronidazole metronidazole njection, metronidazole metronidazole ijection, metronidazole metronidazole inection, metronidazole metronidazole injction, metronidazole metronidazole injetion, metronidazole metronidazole injecion, metronidazole metronidazole injecton, metronidazole metronidazole injectin, metronidazole metronidazole injectio, emtronidazole metronidazole injection, mteronidazole metronidazole injection, mertonidazole metronidazole injection, metornidazole metronidazole injection, metrnoidazole metronidazole injection, metroindazole metronidazole injection, metrondiazole metronidazole injection, metroniadzole metronidazole injection, metronidzaole metronidazole injection, metronidaozle metronidazole injection, metronidazloe metronidazole injection, metronidazoel metronidazole injection, metronidazol e metronidazole injection, metronidazole metronidazole injection, metronidazole m etronidazole injection, metronidazole emtronidazole injection, metronidazole mteronidazole injection, metronidazole mertonidazole injection, metronidazole metornidazole injection, metronidazole metrnoidazole injection, metronidazole metroindazole injection, metronidazole metrondiazole injection, metronidazole metroniadzole injection, metronidazole metronidzaole injection, metronidazole metronidaozle injection, metronidazole metronidazloe injection, metronidazole metronidazoel injection, metronidazole metronidazol einjection, metronidazole metronidazolei njection, metronidazole metronidazole nijection, metronidazole metronidazole ijnection, metronidazole metronidazole inejction, metronidazole metronidazole injcetion, metronidazole metronidazole injetcion, metronidazole metronidazole injeciton, metronidazole metronidazole injectoin, metronidazole metronidazole injectino, mmetronidazole metronidazole injection, meetronidazole metronidazole injection, mettronidazole metronidazole injection, metrronidazole metronidazole injection, metroonidazole metronidazole injection, metronnidazole metronidazole injection, metroniidazole metronidazole injection, metroniddazole metronidazole injection, metronidaazole metronidazole injection, metronidazzole metronidazole injection, metronidazoole metronidazole injection, metronidazolle metronidazole injection, metronidazolee metronidazole injection, metronidazole metronidazole injection, metronidazole metronidazole injection, metronidazole mmetronidazole injection, metronidazole meetronidazole injection, metronidazole mettronidazole injection, metronidazole metrronidazole injection, metronidazole metroonidazole injection, metronidazole metronnidazole injection, metronidazole metroniidazole injection, metronidazole metroniddazole injection, metronidazole metronidaazole injection, metronidazole metronidazzole injection, metronidazole metronidazoole injection, metronidazole metronidazolle injection, metronidazole metronidazolee injection, metronidazole metronidazole injection, metronidazole metronidazole iinjection, metronidazole metronidazole innjection, metronidazole metronidazole injjection, metronidazole metronidazole injeection, metronidazole metronidazole injecction, metronidazole metronidazole injecttion, metronidazole metronidazole injectiion, metronidazole metronidazole injectioon, metronidazole metronidazole injectionn, etc.



© Copyright by drug-information.ru 2001-2019. All rights reserved